273 related articles for article (PubMed ID: 32890458)
1. TIGIT presents earlier expression dynamic than PD-1 in activated CD8
Hu F; Wang W; Fang C; Bai C
Exp Cell Res; 2020 Nov; 396(1):112260. PubMed ID: 32890458
[TBL] [Abstract][Full Text] [Related]
2. Absence of PD-L1 expression on tumor cells in the context of an activated immune infiltrate may indicate impaired IFNγ signaling in non-small cell lung cancer.
Theelen WSME; Kuilman T; Schulze K; Zou W; Krijgsman O; Peters DDGC; Cornelissen S; Monkhorst K; Sarma P; Sumiyoshi T; Amler LC; Willems SM; Blaauwgeers JLG; van Noesel CJM; Peeper DS; van den Heuvel MM; Kowanetz M
PLoS One; 2019; 14(5):e0216864. PubMed ID: 31125352
[TBL] [Abstract][Full Text] [Related]
3. TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.
Chauvin JM; Pagliano O; Fourcade J; Sun Z; Wang H; Sander C; Kirkwood JM; Chen TH; Maurer M; Korman AJ; Zarour HM
J Clin Invest; 2015 May; 125(5):2046-58. PubMed ID: 25866972
[TBL] [Abstract][Full Text] [Related]
4. Role of leukotriene B4 12-hydroxydehydrogenase in α-galactosylceramide-pulsed dendritic cell therapy for non-small cell lung cancer.
Tanaka K; Kanesaka Y; Takami M; Suzuki A; Hosokawa H; Onodera A; Kamata T; Nagato K; Nakayama T; Yoshino I; Motohashi S
Biochem Biophys Res Commun; 2018 Nov; 506(1):27-32. PubMed ID: 30336981
[TBL] [Abstract][Full Text] [Related]
5. CD8
Huang B; Liu R; Wang P; Yuan Z; Yang J; Xiong H; Zhang N; Huang Q; Fu X; Sun W; Li L
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32606053
[TBL] [Abstract][Full Text] [Related]
6. Expression of PD1 and BTLA on the CD8
Bao Y; Mo JF; Wu JY; Cao CX
Chin Med Sci J; 2019 Nov; 34(4):248-255. PubMed ID: 33906710
[No Abstract] [Full Text] [Related]
7. TIGIT and PD-1 may serve as potential prognostic biomarkers for gastric cancer.
Xu D; Zhao E; Zhu C; Zhao W; Wang C; Zhang Z; Zhao G
Immunobiology; 2020 May; 225(3):151915. PubMed ID: 32122675
[TBL] [Abstract][Full Text] [Related]
8. Increased Coexpression of PD-1, TIGIT, and KLRG-1 on Tumor-Reactive CD8
Hutten TJA; Norde WJ; Woestenenk R; Wang RC; Maas F; Kester M; Falkenburg JHF; Berglund S; Luznik L; Jansen JH; Schaap N; Dolstra H; Hobo W
Biol Blood Marrow Transplant; 2018 Apr; 24(4):666-677. PubMed ID: 29197680
[TBL] [Abstract][Full Text] [Related]
9. Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients.
El-Guindy DM; Helal DS; Sabry NM; Abo El-Nasr M
J Egypt Natl Canc Inst; 2018 Dec; 30(4):125-131. PubMed ID: 30337185
[TBL] [Abstract][Full Text] [Related]
10. PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8
Whelan S; Ophir E; Kotturi MF; Levy O; Ganguly S; Leung L; Vaknin I; Kumar S; Dassa L; Hansen K; Bernados D; Murter B; Soni A; Taube JM; Fader AN; Wang TL; Shih IM; White M; Pardoll DM; Liang SC
Cancer Immunol Res; 2019 Feb; 7(2):257-268. PubMed ID: 30659054
[TBL] [Abstract][Full Text] [Related]
11. CD38 identifies pre-activated CD8+ T cells which can be reinvigorated by anti-PD-1 blockade in human lung cancer.
Wu P; Zhao L; Chen Y; Xin Z; Lin M; Hao Z; Chen X; Chen D; Wu D; Chai Y
Cancer Immunol Immunother; 2021 Dec; 70(12):3603-3616. PubMed ID: 33934206
[TBL] [Abstract][Full Text] [Related]
12. PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy.
Simon S; Voillet V; Vignard V; Wu Z; Dabrowski C; Jouand N; Beauvais T; Khammari A; Braudeau C; Josien R; Adotevi O; Laheurte C; Aubin F; Nardin C; Rulli S; Gottardo R; Ramchurren N; Cheever M; Fling SP; Church CD; Nghiem P; Dreno B; Riddell SR; Labarriere N
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33188038
[TBL] [Abstract][Full Text] [Related]
13. CD8
Wang M; Bu J; Zhou M; Sido J; Lin Y; Liu G; Lin Q; Xu X; Leavenworth JW; Shen E
Clin Immunol; 2018 May; 190():64-73. PubMed ID: 28893624
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of PD-L1-positive cancer-associated fibroblasts in pN0M0 non-small cell lung cancer.
Teramoto K; Igarashi T; Kataoka Y; Ishida M; Hanaoka J; Sumimoto H; Daigo Y
Lung Cancer; 2019 Nov; 137():56-63. PubMed ID: 31546072
[TBL] [Abstract][Full Text] [Related]
15. A Systematic Review and Meta-Analysis on the Significance of TIGIT in Solid Cancers: Dual TIGIT/PD-1 Blockade to Overcome Immune-Resistance in Solid Cancers.
Hosseinkhani N; Shadbad MA; Asghari Jafarabadi M; Karim Ahangar N; Asadzadeh Z; Mohammadi SM; Lotfinejad P; Alizadeh N; Brunetti O; Fasano R; Silvestris N; Baradaran B
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638729
[TBL] [Abstract][Full Text] [Related]
16. Early Effector T Lymphocytes Coexpress Multiple Inhibitory Receptors in Primary Non-Small Cell Lung Cancer.
Tassi E; Grazia G; Vegetti C; Bersani I; Bertolini G; Molla A; Baldassari P; Andriani F; Roz L; Sozzi G; Pastorino U; Mortarini R; Anichini A
Cancer Res; 2017 Feb; 77(4):851-861. PubMed ID: 27979840
[TBL] [Abstract][Full Text] [Related]
17. Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8
Li YM; Yu JM; Liu ZY; Yang HJ; Tang J; Chen ZN
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31627272
[TBL] [Abstract][Full Text] [Related]
18. Dynamic changes in PD-L1 expression and CD8
Choe EA; Cha YJ; Kim JH; Pyo KH; Hong MH; Park SY; Shim HS; Jung I; Lee CY; Cho BC; Kim HR
Lung Cancer; 2019 Oct; 136():30-36. PubMed ID: 31421259
[TBL] [Abstract][Full Text] [Related]
19. Follicular cytotoxic CD8 T cells present high cytokine expression, and are more susceptible to Breg-mediated suppression in non-small cell lung cancer.
Ma QY; Chen J; Zhao J
Immunol Res; 2020 Feb; 68(1):54-62. PubMed ID: 32128664
[TBL] [Abstract][Full Text] [Related]
20. CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients.
Djenidi F; Adam J; Goubar A; Durgeau A; Meurice G; de Montpréville V; Validire P; Besse B; Mami-Chouaib F
J Immunol; 2015 Apr; 194(7):3475-86. PubMed ID: 25725111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]